Cargando…

Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study

Excessive activation of the mineralocorticoid receptor (MR) underlies the pathophysiology of heart failure and chronic kidney disease. Hyperkalemia risk limits the therapeutic use of conventional MR antagonists. AZD9977 is a nonsteroidal, selective MR modulator that may protect nonepithelial tissues...

Descripción completa

Detalles Bibliográficos
Autores principales:	Whittaker, Andrew, Kragh, Åsa M., Hartleib‐Geschwindner, Judith, Albayaty, Muna, Backlund, Anna, Greasley, Peter J., Heijer, Maria, Kjaer, Magnus, Forte, Pablo, Unwin, Robert, Wernevik, Linda, Ericsson, Hans
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070793/ https://www.ncbi.nlm.nih.gov/pubmed/31584739 http://dx.doi.org/10.1111/cts.12705

Ejemplares similares

The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone
por: Bamberg, Krister, et al.
Publicado: (2019)

Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial
por: Squire, Iain B., et al.
Publicado: (2022)

Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion
por: Bamberg, Krister, et al.
Publicado: (2018)

Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability
por: Ericsson, Hans, et al.
Publicado: (2019)

Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies
por: Balaguer, Victor, et al.
Publicado: (2020)

Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator
por: Jimenez, Eulalia, et al.
Publicado: (2020)

Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice
por: Palacios-Ramirez, Roberto, et al.
Publicado: (2022)

Safety, tolerability, pharmacokinetics and effect on serum uric acid of the myeloperoxidase inhibitor AZD4831 in a randomized, placebo‐controlled, phase I study in healthy volunteers
por: Gan, Li‐Ming, et al.
Publicado: (2019)

Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction
por: Nelander, Karin, et al.
Publicado: (2021)

Initial Clinical Experience with AZD5718, a Novel Once Daily Oral 5‐Lipoxygenase Activating Protein Inhibitor
por: Ericsson, Hans, et al.
Publicado: (2018)

Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults
por: Forte-Soto, Pablo, et al.
Publicado: (2023)

Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects
por: Knöchel, Jane, et al.
Publicado: (2021)

Electrolyte handling in the isolated perfused rat kidney: demonstration of vasopressin V2-receptor-dependent calcium reabsorption
por: Bamberg, Krister, et al.
Publicado: (2020)

Mineralocorticoid hypertension
por: Gupta, Vishal
Publicado: (2011)

Expression of genes encoding mineralocorticoid biosynthetic enzymes and the mineralocorticoid receptor, and levels of mineralocorticoids in the bovine follicle and corpus luteum
por: MUKANGWA, Memory, et al.
Publicado: (2019)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Evaluation of the Pharmacokinetic Interaction between Lesogaberan (AZD3355) and Esomeprazole in Healthy Subjects
por: Niazi, Mohammad, et al.
Publicado: (2012)

Principal function of mineralocorticoid signaling suggested by constitutive knockout of the mineralocorticoid receptor in medaka fish
por: Sakamoto, Tatsuya, et al.
Publicado: (2016)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers
por: Tezuka, Yuta, et al.
Publicado: (2022)

The Pharmacokinetics and Relative Bioavailability of Mepolizumab 100 mg Liquid Formulation Administered Subcutaneously to Healthy Participants: A Randomized Trial
por: Shabbir, Shaila, et al.
Publicado: (2019)

Mineralocorticoid receptor blockade for renoprotection
por: Cha, Dae Ryong
Publicado: (2018)

A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease
por: Nygaard, Haakon B, et al.
Publicado: (2015)

Importance of Micromilieu for Pathophysiologic Mineralocorticoid Receptor Activity—When the Mineralocorticoid Receptor Resides in the Wrong Neighborhood
por: Griesler, Bruno, et al.
Publicado: (2022)

Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists
por: Mende, Christian W., et al.
Publicado: (2023)

Ascending Thoracic Aortic Dissection: A Case Report of Rapid Detection Via Emergency Echocardiography with Suprasternal Notch Views
por: Backlund, Brandon, et al.
Publicado: (2020)

Why are mineralocorticoid receptor antagonists cardioprotective?
por: Chai, Wenxia, et al.
Publicado: (2006)

Localization of Mineralocorticoid Receptors at Mammalian Synapses
por: Prager, Eric M., et al.
Publicado: (2010)

Mineralocorticoid hypertension and hypokalaemia induced by posaconazole
por: Boughton, Charlotte, et al.
Publicado: (2018)

Aldosterone and Mineralocorticoid Receptors—Physiology and Pathophysiology
por: Funder, John W.
Publicado: (2017)

Posaconazole-Induced Apparent Mineralocorticoid Excess
por: Pandit, Amar, et al.
Publicado: (2020)

Cardiovascular Remodeling in Chronic Mineralocorticoid Excess
por: Bhattad, Pradnya Brijmohan, et al.
Publicado: (2023)

Effect of Oral Semaglutide on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol in Healthy Postmenopausal Women and Furosemide and Rosuvastatin in Healthy Subjects
por: Jordy, Andreas B., et al.
Publicado: (2021)

Safety, Pharmacokinetics and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Velsecorat (AZD7594) Following Inhalation in Healthy Volunteers
por: Prothon, Susanne, et al.
Publicado: (2022)

Pharmacokinetic Profile of Lesogaberan (AZD3355) in Healthy Subjects: A Novel GABA(B)-Receptor Agonist Reflux Inhibitor
por: Niazi, Mohammad, et al.
Publicado: (2012)

Mineralocorticoid Deficiency and Treatment in Congenital Adrenal Hyperplasia
por: Padidela, Raja, et al.
Publicado: (2010)

Aldosterone and the mineralocorticoid receptor in the cerebral circulation and stroke
por: Dinh, Quynh N, et al.
Publicado: (2012)

Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone
por: Muñoz-Durango, N., et al.
Publicado: (2015)

Mineralocorticoid Receptors in the Pathophysiology of Vascular Inflammation and Atherosclerosis
por: Moss, Mary E., et al.
Publicado: (2015)

Roles of the Glucocorticoid and Mineralocorticoid Receptors in Skin Pathophysiology
por: Sevilla, Lisa M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5phsqdrqslc9is235ie4jlilcl